期刊
ANTIVIRAL RESEARCH
卷 126, 期 -, 页码 117-124出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2015.12.012
关键词
Chikungunya virus; Antiviral screening; Alphavirus; RNA replication; Yellow fever virus
资金
- EU [261202]
- Academy of Finland [265997]
- Academy of Finland (AKA) [265997, 265997] Funding Source: Academy of Finland (AKA)
Chikungunya virus (CHIKV) is an arthritogenic arbovirus of the Alphavirus genus, which has infected millions of people after its re-emergence in the last decade. In this study, a BHK cell line containing a stable CHIKV replicon with a luciferase reporter was used in a high-throughput platform to screen approximately 3000 compounds. Following initial validation, 25 compounds were chosen as primary hits for secondary validation with wild type and reporter CHIKV infection, which identified three promising compounds. Abamectin (EC50 = 1.5 mu M) and ivermectin (EC50 = 0.6 mu M) are fermentation products generated by a soil dwelling actinomycete, Streptomyces avermitilis, whereas berberine (EC50 = 1.8 mu M) is a plant-derived isoquinoline alkaloid. They inhibited CHIKV replication in a dose-dependent manner and had broad antiviral activity against other alphaviruses - Semliki Forest virus and Sindbis virus. Abamectin and ivermectin were also active against yellow fever virus, a flavivirus. These compounds caused reduced synthesis of CHIKV genomic and antigenomic viral RNA as well as downregulation of viral protein expression. Time of addition experiments also suggested that they act on the replication phase of the viral infectious cycle. (C) 2016 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据